How PBPK Modeling Can Replace Drug-Drug Interaction Studies
Patients often take more than one drug at a time, especially elderly patients and those…
Certara2020 年 11 月 12 日
Certara Opens New China Office in Shanghai
Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D …
Certara2020 年 11 月 9 日
PBPK modeling supports approval of breakthrough cancer drug
Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US…
Certara2020 年 10 月 23 日
SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
Certara2020 年 10 月 20 日
Best Practices for Small to Mid-Size Companies to Advance Drug Discovery Programs
有能力根据研究需求进行扩展是成功的关键。Understanding when the…
Certara2020 年 10 月 12 日
